Drawing for PERINESTA

USPTO serial 79268392

PERINESTA

Reviewed by CopyMark Law Group

Reg. 6132536Status 700Renewal
Filing date
Status date
Registration date
Aug 25, 2020
Examiner
BLAZICH, JOAN MICHELE
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with PERINESTA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*

Plus Government fees of $850

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Martin W. Schiffmiller

Martin W. Schiffmiller Kirschstein Israel Schiffmiller & Pieron425 Fifth Avenue, Fifth Floor, Suite 501New York, NY 10016-2223UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical products in the field of gynecology and women's health, including for treating symptoms of perimenopause and menopause, namely, oral and chemical contraceptives, hormones for medical purposes, hormone replacement therapy preparations, estrogen preparations; oral contraceptives; chemical contraceptives; hormonal preparations for pharmaceutical use; contraceptives for treating symptoms of perimenopause and menopause, namely, oral contraceptives, contraceptive preparations and contraceptive foamsACTIVE—
042Pharmaceutical research and development services; testing on pharmaceutical products; carrying out clinical trials for others for pharmaceutical products; development of pharmaceutical preparations and medicines; consultancy with respect to pharmaceutical research and development; laboratory research services concerning pharmaceutical products; services for conducting early assessments of new pharmaceuticals, namely, testing of new pharmaceuticals; provision of information in connection with medical and scientific research in the field of pharmaceutical products and clinical trials; provision of information concerning the results of clinical trials for pharmaceutical products, namely, providing information on testing, inspection or research of pharmaceuticalsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 25, 2025REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jan 28, 2024ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Jan 5, 2024NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 11, 2022ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Mar 13, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 19, 2020FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Dec 2, 2020FICSFINAL DISPOSITION NOTICE SENT TO IB—
Dec 1, 2020FIMPFINAL DISPOSITION PROCESSED—
Nov 25, 2020FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Aug 25, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 12, 2020GPNXNOTIFICATION PROCESSED BY IB—
Jun 9, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 9, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 27, 2020OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
May 27, 2020OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
May 20, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 6, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 5, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 5, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 5, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 5, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 5, 2020ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
May 5, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 5, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 5, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 5, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 22, 2019RFNTREFUSAL PROCESSED BY IB—
Nov 7, 2019RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Nov 7, 2019RFRRREFUSAL PROCESSED BY MPU—
Oct 19, 2019RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Oct 18, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 14, 2019DOCKASSIGNED TO EXAMINER—
Oct 8, 2019MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 4, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 26, 2019REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance